Guerbet has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Lipiojoint, the company’s transient liquid embolic agent designed to alleviate pain and the related burden of reduced mobility in patients with knee osteoarthritis (OA).
This recognition highlights the potential of Lipiojoint as a minimally invasive and targeted approach for knee OA patients who have not found relief through non-surgical treatment modalities.
“Being part of the Lipiojoint FDA Breakthrough programme is a major milestone for Guerbet but most importantly for patients suffering from osteoarthritis. Working closely with the US administration will give a unique opportunity to bring an innovative approach aiming to release pain for a large part of the population. A unique collaboration for a medical unmet need” said Dan Raffi, global chief commercial officer and president for Gubert France.
